目的评价皮下注射硼替佐米治疗多发性骨髓瘤的疗效及安全性。方法计算机检索皮下注射硼替佐米治疗多发性骨髓瘤的随机对照试验,根据改良版Jadad量表评价纳入研究的质量,提取数据后,使用Stata SE12.0进行Meta分析,依据系统综述和Meta分析优先报告条目(PRISMA声明)进行结果报告。结果共纳入4篇文献,包括1 088例患者,皮下注射组与静脉注射组总反应率比较无统计学差异,但周围神经症[RR=0.70,95%CI(0.58,0.85)]和腹泻[RR=0.68,95%CI(0.52,0.89)]的总发生率差异有统计学意义(P<0.05)。结论与静脉注射用药方式相比,皮下注射用药方式不影响硼替佐米治疗多发性骨髓瘤的疗效,但可以降低周围神经症与腹泻的发生率,具有更好的安全性。 Objective To evaluate the efficacy and safety of subcutaneous injection of bortezomib in the treatment of multiple myeloma. METHODS: Randomized controlled trials of subcutaneous injections of bortezomib for the treatment of multiple myeloma were performed by computer. The quality of the study was evaluated according to the modified version of Jadad. The data were extracted and analyzed using Stata SE12.0 for Meta analysis, based on systematic reviews and Meta analysis Report item (PRISMA statement) to report the result. Results A total of 4 articles were included, including 1 088 patients. There was no significant difference in the overall response rate between subcutaneous injection and intravenous injection. However, peripheral neurosis [RR = 0.70, 95% CI (0.58, 0.85)] and diarrhea The overall incidence of RR = 0.68,95% CI (0.52,0.89)] was significantly different (P <0.05). Conclusion Compared with intravenous injection, subcutaneous injection does not affect the efficacy of bortezomib in the treatment of multiple myeloma, but can reduce the incidence of peripheral neurosis and diarrhea, with better safety.